Opaleye Management Inc., Opaleye, L.P., and James Silverman filed Amendment No. 10 to their beneficial ownership statement with the SEC on November 6, 2026, reporting a combined 2,105,000 shares of Harrow, Inc. common stock as of September 30, 2026.

Key Highlights

  • Three reporting persons: Opaleye Management Inc., Opaleye, L.P., and James Silverman each report 2,105,000 shares of Harrow, Inc. common stock beneficially owned.
  • 5.62% ownership: The aggregate 2,105,000 shares represent 5.62% of Harrow, Inc.'s outstanding common stock, based on 37,487,850 shares outstanding as of August 6, 2026.
  • Shared voting and dispositive power: All 2,105,000 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as zero.
  • Direct holder: According to the filing, Opaleye, L.P. directly holds the 2,105,000 shares; Opaleye Management Inc. and James Silverman are deemed beneficial owners through their roles as investment adviser and controlling person, respectively.
  • Fund dividend entitlement: The filing states that Opaleye, L.P. is entitled to receive dividends from, and proceeds from the sale of, the shares reported, and that the fund's interest exceeds 5% of the outstanding common stock.
  • Event date: The date of event requiring this filing is reported as September 30, 2026.

Opaleye Group Reports Passive 5.62% Position in Harrow Common Stock

According to the filing, Opaleye Management Inc., a Massachusetts-incorporated investment adviser, and its affiliated Delaware limited partnership Opaleye, L.P., together with James Silverman as the controlling person of the adviser, collectively report beneficial ownership of 2,105,000 shares of Harrow, Inc. common stock, par value $0.001 per share (CUSIP 415858109). The shares represent 5.62% of the class, calculated using 37,487,850 shares outstanding as of August 6, 2026, as reported by Harrow, Inc. in its Form 10-Q filed with the SEC on August 10, 2026. Harrow, Inc., the issuer, is a pharmaceutical company headquartered at 1A Burton Hills Blvd., Suite 200, Nashville, TN 37215, as identified in the filing.

The filing is Amendment No. 10, indicating this group has previously reported its position on multiple occasions. The reporting persons certified that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," consistent with a passive investment posture. The filing addresses voting and dispositive authority: sole voting power and sole dispositive power are both zero for each reporting person, while shared voting power and shared dispositive power each equal 2,105,000 shares, reflecting the structure in which the fund holds shares directly while the adviser and controlling person are deemed beneficial owners through that relationship.

The filing was signed by James Silverman on November 6, 2026, in his capacity as President of Opaleye Management Inc., as Managing Member of Opaleye GP LLC (the general partner of Opaleye, L.P.), and individually. A Joint Filing Agreement among the reporting persons is attached as Exhibit 99.1.

What Was Disclosed

Opaleye Management Inc., Opaleye, L.P., and James Silverman filed Amendment No. 10 to their beneficial ownership report for Harrow, Inc. common stock, disclosing 2,105,000 shares, equal to 5.62% of the class, with a triggering event date of September 30, 2026.